Effect of hepatitis C virus and its treatment on survival
The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and H...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2009-08, Vol.50 (2), p.387-392 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 392 |
---|---|
container_issue | 2 |
container_start_page | 387 |
container_title | Hepatology (Baltimore, Md.) |
container_volume | 50 |
creator | Butt, Adeel A. Wang, Xiaoqiang Moore, Charity G. |
description | The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.) |
doi_str_mv | 10.1002/hep.23000 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67550732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67550732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</originalsourceid><addsrcrecordid>eNp10L1OwzAUBWALgWgpDLwA8gISQ9prO8bxiKpCkSrB0N1yHFsY5afYSVHfnpREMDHd5dM5ugehawJzAkAX73Y3pwwATtCUcCoSxjicoilQAYkkTE7QRYwfPZApzc7RhEguCaHZFMmVc9a0uHG4T9Gtb33ES7z3oYtY1wX2bcRtsLqtbN2zGscu7P1el5fozOky2qvxztD2abVdrpPN6_PL8nGTmJSnkGRgeJEWlvFMu5RJKqyDHGhhgBvDCTiwLAfIrRQ0z1MnJCUu0yAhLYRlM3Q3xO5C89nZ2KrKR2PLUte26aJ6EJyDYLSH9wM0oYkxWKd2wVc6HBQBdZxJ9Q-qn5l6ezOGdnlliz857tKD2xHoaHTpgq6Nj7-OEpGRjB5LF4P78qU9_N-o1qu3ofob64l89g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67550732</pqid></control><display><type>article</type><title>Effect of hepatitis C virus and its treatment on survival</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Butt, Adeel A. ; Wang, Xiaoqiang ; Moore, Charity G.</creator><creatorcontrib>Butt, Adeel A. ; Wang, Xiaoqiang ; Moore, Charity G.</creatorcontrib><description>The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.23000</identifier><identifier>PMID: 19591128</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antiviral Agents - therapeutic use ; Biological and medical sciences ; Case-Control Studies ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis C - drug therapy ; Hepatitis C - mortality ; Humans ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; United States - epidemiology ; Veterans</subject><ispartof>Hepatology (Baltimore, Md.), 2009-08, Vol.50 (2), p.387-392</ispartof><rights>Copyright © 2009 American Association for the Study of Liver Diseases</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</citedby><cites>FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.23000$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.23000$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21781822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19591128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Butt, Adeel A.</creatorcontrib><creatorcontrib>Wang, Xiaoqiang</creatorcontrib><creatorcontrib>Moore, Charity G.</creatorcontrib><title>Effect of hepatitis C virus and its treatment on survival</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)</description><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - mortality</subject><subject>Humans</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>United States - epidemiology</subject><subject>Veterans</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L1OwzAUBWALgWgpDLwA8gISQ9prO8bxiKpCkSrB0N1yHFsY5afYSVHfnpREMDHd5dM5ugehawJzAkAX73Y3pwwATtCUcCoSxjicoilQAYkkTE7QRYwfPZApzc7RhEguCaHZFMmVc9a0uHG4T9Gtb33ES7z3oYtY1wX2bcRtsLqtbN2zGscu7P1el5fozOky2qvxztD2abVdrpPN6_PL8nGTmJSnkGRgeJEWlvFMu5RJKqyDHGhhgBvDCTiwLAfIrRQ0z1MnJCUu0yAhLYRlM3Q3xO5C89nZ2KrKR2PLUte26aJ6EJyDYLSH9wM0oYkxWKd2wVc6HBQBdZxJ9Q-qn5l6ezOGdnlliz857tKD2xHoaHTpgq6Nj7-OEpGRjB5LF4P78qU9_N-o1qu3ofob64l89g</recordid><startdate>200908</startdate><enddate>200908</enddate><creator>Butt, Adeel A.</creator><creator>Wang, Xiaoqiang</creator><creator>Moore, Charity G.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200908</creationdate><title>Effect of hepatitis C virus and its treatment on survival</title><author>Butt, Adeel A. ; Wang, Xiaoqiang ; Moore, Charity G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4540-80c5d4de358af43927ef0b02dc05cc510f0e3b00be972bb4f7921f8a0904d7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - mortality</topic><topic>Humans</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>United States - epidemiology</topic><topic>Veterans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Butt, Adeel A.</creatorcontrib><creatorcontrib>Wang, Xiaoqiang</creatorcontrib><creatorcontrib>Moore, Charity G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Butt, Adeel A.</au><au>Wang, Xiaoqiang</au><au>Moore, Charity G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of hepatitis C virus and its treatment on survival</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2009-08</date><risdate>2009</risdate><volume>50</volume><issue>2</issue><spage>387</spage><epage>392</epage><pages>387-392</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV‐infected veterans and uninfected controls. We used a national sample of HCV‐infected persons and HCV‐uninfected controls from the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) to compare survival between the two groups. We also compared the effect of treatment and treatment duration on survival in the HCV‐infected group. We used matched Cox proportional hazards model to determine the predictors of mortality. Kaplan‐Meier survival plots were generated to determine and compare survival among HCV‐infected and HCV‐uninfected persons, and among treated and untreated HCV‐infected persons.We identified 34,480 matched pairs of HCV‐infected subjects and controls. HCV infection was independently associated with a higher risk of mortality (hazards ratio, 1.37; 95% confidence interval, 1.31‐1.47). Subjects treated for 48 weeks or longer had the lowest mortality among HCV‐infected subjects (hazards ratio, 0.41; 95% confidence interval, 0.27‐0.64), whereas those who received less than 48 week of treatment had intermediate mortality (hazards ratio, 0.71 and 0.60 for 0‐23 weeks and 24‐47 weeks of treatment, respectively) compared with untreated subjects. Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>19591128</pmid><doi>10.1002/hep.23000</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-9139 |
ispartof | Hepatology (Baltimore, Md.), 2009-08, Vol.50 (2), p.387-392 |
issn | 0270-9139 1527-3350 |
language | eng |
recordid | cdi_proquest_miscellaneous_67550732 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Antiviral Agents - therapeutic use Biological and medical sciences Case-Control Studies Female Gastroenterology. Liver. Pancreas. Abdomen Hepatitis C - drug therapy Hepatitis C - mortality Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged United States - epidemiology Veterans |
title | Effect of hepatitis C virus and its treatment on survival |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A08%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20hepatitis%20C%20virus%20and%20its%20treatment%20on%20survival&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Butt,%20Adeel%20A.&rft.date=2009-08&rft.volume=50&rft.issue=2&rft.spage=387&rft.epage=392&rft.pages=387-392&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.23000&rft_dat=%3Cproquest_cross%3E67550732%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67550732&rft_id=info:pmid/19591128&rfr_iscdi=true |